Osiris Therapeutics Inc (OSIR)

4.97
0.15 2.90
NASDAQ : Health Care
Prev Close 5.12
Open 5.12
Day Low/High 4.95 / 5.26
52 Wk Low/High 3.55 / 20.42
Volume 81.99K
Avg Volume 86.70K
Exchange NASDAQ
Shares Outstanding 34.45M
Market Cap 179.15M
EPS -0.10
P/E Ratio 104.00
Div & Yield N.A. (N.A)

Latest News

MiMedx Goes After Osiris With Lawsuit

MiMedx Goes After Osiris With Lawsuit

The wound care provider filed the suit for allegedly falsifying and misleading consumers with clinical data.

Osiris Provides Update Regarding NASDAQ Listing Matters

Osiris Provides Update Regarding NASDAQ Listing Matters

Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the "Company"), today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market ("NASDAQ").

Osiris To Present At The 26th European Wound Management Association Conference

Osiris To Present At The 26th European Wound Management Association Conference

Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present...

Osiris Therapeutics Enters Oversold Territory (OSIR)

Osiris Therapeutics Enters Oversold Territory (OSIR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Grafix Demonstrates Superior Clinical Outcomes Compared With EpiFix In

Grafix Demonstrates Superior Clinical Outcomes Compared With EpiFix In "Real World" Study

Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company, focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine,...

Osiris To Present 15 Advanced Clinical And Scientific Abstracts

Osiris To Present 15 Advanced Clinical And Scientific Abstracts

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present...

Osiris Announces Further Expansion Of Grafix Commercial Coverage

Osiris Announces Further Expansion Of Grafix Commercial Coverage

Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine,...

Osiris Therapeutics Stock Sees Short Interest Fall 19%

Osiris Therapeutics Stock Sees Short Interest Fall 19%

The most recent short interest data has been released by the NASDAQ for the 03/15/2016 settlement date, which shows a 896,133 share decrease in total short interest for Osiris Therapeutics Inc , to 3,829,449, a decrease of 18.96% since 02/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Osiris Therapeutics Announces Receipt Of Deficiency Letter From NASDAQ

Osiris Therapeutics Announces Receipt Of Deficiency Letter From NASDAQ

Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine,...

Osiris Therapeutics To Present At The 4th Annual Cell And Gene Therapy Investor Day

Osiris Therapeutics To Present At The 4th Annual Cell And Gene Therapy Investor Day

Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine,...

Osiris Provides An Update On A Clinical Review By Blue Cross Blue Shield Association

Osiris Provides An Update On A Clinical Review By Blue Cross Blue Shield Association

Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine,...

Relative Strength Alert For Osiris Therapeutics

Relative Strength Alert For Osiris Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of March 18th Options Trading For Osiris Therapeutics (OSIR)

First Week of March 18th Options Trading For Osiris Therapeutics (OSIR)

Investors in Osiris Therapeutics Inc saw new options become available this week, for the March 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OSIR options chain for the new March 18th contracts and identified the following call contract of particular interest.

Grafix Demonstrates Positive Clinical Outcomes In Chronic Complex Wounds With Exposed Tendon And Bone

Grafix Demonstrates Positive Clinical Outcomes In Chronic Complex Wounds With Exposed Tendon And Bone

Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine,...

Osiris Confirms Dwayne Montgomery, As President And Chief Executive Officer, And The Election Of Thomas M. Brandt To The Board Of Directors

Osiris Confirms Dwayne Montgomery, As President And Chief Executive Officer, And The Election Of Thomas M. Brandt To The Board Of Directors

Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, is...

Short Interest In Osiris Therapeutics Makes 16% Move

Short Interest In Osiris Therapeutics Makes 16% Move

The most recent short interest data has been released by the NASDAQ for the 01/29/2016 settlement date, which shows a 593,706 share increase in total short interest for Osiris Therapeutics Inc , to 4,277,683, an increase of 16.12% since 01/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Osiris Therapeutics Announces Leadership Transition

Osiris Therapeutics Announces Leadership Transition

Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine,...

Osiris Announces 100% Medicare Coverage For Grafix

Osiris Announces 100% Medicare Coverage For Grafix

Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine,...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: HOLX, NOW, ZHNE Downgrades: ALJ, APAM, EFII, ESE, FNBC, HAIN, INVN, JOUT, LOGM, NSC, NYCB, OSIR, RES, ROK, SHOR, TATT, UTX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Osiris Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of January 22, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Osiris Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of January 22, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Osiris Therapeutics, Inc.

Osiris Responds To Statements About The Company Recently Posted To Several Websites

Osiris Responds To Statements About The Company Recently Posted To Several Websites

Osiris Therapeutics, Inc. (NASDAQ: OSIR) - Today, Osiris Therapeutics, Inc.